Tag: Daxxify

All

The deal expands Crown’s presence in the aesthetics market, bringing Daxxify and the RHA Collection into its portfolio.

Incyte’s sNDA for ruxolitinib cream in children ages 2–11 now faces a new action date to allow additional data review.